 |
|
|
| |
HCC Risk Scores: Application of the CU-HCC, GAG-HCC, and PAGE-B Scores to
Chronic Hepatitis B Patients Treated With Tenofovir Disoproxil Fumarate (TDF)
|
| |
| |
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
W. Ray Kim,1 Rohit Loomba,2 Thomas Berg,3 Raul Aguilar Schall,4 Leland J. Yee,4 Phillip Dinh,4 John F. Flaherty,4 Eduardo B. Martins,4 Ira Jacobson,5 Scott Fung,6 Selim Gurel,7 Maria Buti,8 Patrick Marcellin9
1Stanford University School of Medicine, Palo Alto, California, USA; 2University of California at San Diego, La Jolla, California, USA; 3Universitätsklinikum Leipzig, Germany; 4Gilead Sciences, Inc., Foster City, California, USA; 5Weill Cornell Medical College, New York, New York, USA; 6University of Toronto, Toronto, Ontario, Canada; 7University of Uludag, Bursa, Turkey; 8Hospital General Universitari Vall d'Hebron and Ciberehd del Instituto Carlos III, Barcelona, Spain; 9Hôpital Beaujon, Université Paris Diderot and INSERM CRI/UMR 1149, Viral Hepatitis Research Centre, Clichy, France
|
| |
|
|
|
|
|
